Clinical trial · Observational
Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| EGFR Exon 19 Deletion Mutation | — | UNRESOLVED | — |
| Lung Cancer - Non Small Cell | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood draw | Other | — | UNRESOLVED |
| Gene sequencing | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- EGFR Positive Lung Cancer
- description
- Subjects diagnosed with EGFR positive lung cancer
- interventionNames
- Other: blood draw
- Other: Gene sequencing
- label
- Healthy Subjects
- description
- Subjects who do not have a cancer diagnosis
- interventionNames
- Other: blood draw
- Other: Gene sequencing
Primary outcomes (1)
- measure
- Differences in DNA sequence of EGFR gene
- timeFrame
- From enrollment to end of data analysis at 6 months
- description
- Subjects who have EGFR positive lung cancer will have their gene sequence compared to those that are EGFR negative and do not have lung cancer to look for differences in the sequence.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * 18-100 years old * Biologically born female * Diagnosed with EGFR positive lung cancer (Arm 1-Cancer group) * No cancer diagnosis (Arm 2-health control) Exclusion Criteria: * less than 18 years of age * Biologically born male * Incarcerated at the time of participation
References
Publications (0)
Data not yet available